HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.

@article{Smith1991HMGCoARI,
  title={HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.},
  author={P. F. Smith and R S Eydelloth and Scott J. Grossman and Richard J. Stubbs and Michael S. Schwartz and John Germershausen and Kamlesh P Vyas and Prasad H Kari and James S Macdonald},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1991},
  volume={257 3},
  pages={1225-35}
}
Recent clinical evidence indicates a potential for skeletal muscle toxicity after therapy with HMG-CoA reductase inhibitors (HMGRIs) in man. Although the incidence of drug-induced skeletal muscle toxicity is very low (0.1-0.2%) with monotherapy, it may increase following concomitant drug therapy with the immunosuppressant, cyclosporine A (CsA), and possibly with certain other hypolipidemic agents. In the Sprague-Dawley rat, very high, pharmacologically comparable dosages (150-1200 mg/kg/day) of… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
MyopathyNo subtypeMyalgia
Doses of HMGRIs which did not produce skeletal muscle toxicity when given alone caused between 75 and 100% incidence of myopathy ( very slight to marked skeletal muscle degeneration ) when CsA was coadministered .
MyopathyNo subtypeMyalgia
Doses of HMGRIs which did not produce skeletal muscle toxicity when given alone caused between 75 and 100% incidence of myopathy ( very slight to marked skeletal muscle degeneration ) when CsA was coadministered .
Doses of HMGRIs which did not produce skeletal muscle toxicity when given alone caused between 75 and 100% incidence of myopathy ( very slight to marked skeletal muscle degeneration ) when CsA was coadministered .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Although the incidence of drug - induced skeletal muscle toxicity is very low ( 0.1 - 0.2% ) with monotherapy , it may increase following concomitant drug therapy with the immunosuppressant , cyclosporine A ( CsA ) , and possibly with certain other hypolipidemic agents .
Recent clinical evidence indicates a potential for skeletal muscle toxicity after therapy with HMG - CoA reductase inhibitors ( HMGRIs ) in man .
Recent clinical evidence indicates a potential for skeletal muscle toxicity after therapy with HMG - CoA reductase inhibitors ( HMGRIs ) in man .
Recent clinical evidence indicates a potential for skeletal muscle toxicity after therapy with HMG - CoA reductase inhibitors ( HMGRIs ) in man .
Recent clinical evidence indicates a potential for skeletal muscle toxicity after therapy with HMG - CoA reductase inhibitors ( HMGRIs ) in man .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
In the Sprague - Dawley rat , very high , pharmacologically comparable dosages ( 150 - 1200 mg / kg / day ) of structurally similar HMGRIs ( lovastatin , simvastatin , pravastatin and L-647 , 318 ) produced dose - related increases in the incidence and severity of skeletal muscle degeneration .
MyalgiaNo subtypeMyopathy
Doses of HMGRIs which did not produce skeletal muscle toxicity when given alone caused between 75 and 100% incidence of myopathy ( very slight to marked skeletal muscle degeneration ) when CsA was coadministered .
MyalgiaNo subtypeMyopathy
Doses of HMGRIs which did not produce skeletal muscle toxicity when given alone caused between 75 and 100% incidence of myopathy ( very slight to marked skeletal muscle degeneration ) when CsA was coadministered .
All Topics